These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 17341170

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F, Reggio A.
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD.
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD.
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [Abstract] [Full Text] [Related]

  • 15. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS, European NABINMS Consortium.
    J Int Med Res; 2008 Dec; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract] [Full Text] [Related]

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Disease-modifying therapy in multiple sclerosis: update and clinical implications.
    Goodin DS.
    Neurology; 2008 Dec 09; 71(24 Suppl 3):S8-13. PubMed ID: 19064873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.